^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    camonsertib (RP-3500)

    i
    Associations
    News

    Trials

    Company:
    Repare Therap
    Drug class:
    ATR inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (Morpheus Lung) (NCT03337698)
    Phase 1/2
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    12/27/2017
    Primary completion :
    09/30/2025
    Completion :
    11/30/2026
    PD-L1
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine • docetaxel • Cotellic (cobimetinib) • pemetrexed • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • Repatha (evolocumab) • camonsertib (RP-3500) • cibisatamab (RG7802) • ciforadenant (CPI-444) • zanzalintinib (XL092)
    Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study (NCT04589845)
    Phase 2
    Hoffmann-La Roche
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    01/18/2021
    Primary completion :
    09/25/2032
    Completion :
    09/25/2032
    BRAF
    |
    Tecentriq (atezolizumab) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Kadcyla (ado-trastuzumab emtansine) • Gavreto (pralsetinib) • ipatasertib (RG7440) • belvarafenib (RG6185) • idasanutlin (RG7388) • divarasib (RG6330) • Itovebi (inavolisib) • camonsertib (RP-3500)
    A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer (NCT05566574)
    Phase 1/2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    03/15/2024
    Initiation :
    09/30/2022
    Primary completion :
    09/30/2025
    Completion :
    09/30/2025
    ATM
    |
    ATM mutation • ATM deletion
    |
    camonsertib (RP-3500)
    RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia (CORONADO CLL) (NCT05405309)
    Phase 1/2
    University of Utah
    Recruiting
    Last update posted :
    02/13/2024
    Initiation :
    09/23/2022
    Primary completion :
    08/15/2025
    Completion :
    08/15/2027
    TP53 • BCL2 • CD20 • SF3B1 • CCND1 • CD5 • POT1 • FCER2
    |
    TP53 mutation • ATM mutation • Chr t(11;14) • SF3B1 mutation
    |
    Lynparza (olaparib) • camonsertib (RP-3500)